{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-025329","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.653171+00:00","generated_at":"2026-05-21T09:28:03.203197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ADC Therapeutics Q1 net loss narrows to $38.6M; ZYNLONTA revenue $17.4M, LOTIS-7 shows 95.5% ORR","bullets":["Q1 product revenue $17.4M vs $17.8M YoY; license revenue $5.6M including $5M Canadian milestone.","Net loss $38.6M ($0.36/sh) vs $46.6M ($0.56); adjusted net loss $24.0M ($0.22).","Cash $194.7M at March 31; runway expected into H2 2026.","LOTIS-7 (ZYNLONTA+glofitamab) enrolled 40 patients; abstract shows 95.5% ORR, 90.9% CR.","LOTIS-5 confirmatory trial on track for PFS events by end of 2025; ADCT-602 discontinued."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-025329","json":"https://secwatch.observer/filing/0001628280-25-025329.json","markdown":"https://secwatch.observer/filing/0001628280-25-025329.md","text":"https://secwatch.observer/filing/0001628280-25-025329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000162828025025329/0001628280-25-025329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000162828025025329/adc-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:28:03.203197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}